Masonic Cancer Center News
CETI: A jump-start for new cancer therapies
Promising cancer research often stalls out at the concept level because there’s no funding to complete it.
To help get more ideas from the lab into the clinic, the Masonic Cancer Center recently created the Cancer Experimental Therapeutics Initiative (CETI). Director Jeffrey Miller, M.D., says CETI is being established to create the infrastructure needed to help move the best basic science research into clinical trials faster and double the number of patients enrolled in clinical trials at the University of Minnesota in the next five years.
Because translational research is expensive, CETI was designed to advance ideas that will eventually be funded by the National Institutes of Health, the major source of funding for sustainable medical research.
But to have a good chance of securing those grants, researchers must already have clinical trials in progress. That’s where CETI comes in — and why CETI will rely mainly on private funding and philanthropy to sustain it, says Miller.
“Philanthropic dollars give us the freedom to invest in the future,” he says, because the most novel ideas test new boundaries. “But innovation is important to make new strides in cancer therapies.”
To learn more about how you can support the Cancer Experimental Therapeutics Initiative at the Masonic Cancer Center, contact Catherine McGlinch at 612-626-5456 or email@example.com.